IPHA logo

IPHA Innate Pharma S.A.

NASDAQ Global Select · Biotechnology · Healthcare

$0.94
-0.10 (-9.22%)

Innate Pharma S.A. is a biotechnology firm dedicated to the discovery, development, and commercialization of innovative antibody-based therapies, primarily for cancer indications, operating both in France and internationally. The company's pipeline includes several key drug candidates: Lacutamab (IPH4102), an anti-KIR3DL2 antibody, is currently in Phase II clinical trials for treating cutaneous T-…

Market Cap: $104.44Mwww.innate-pharma.com

Price

No data yet.

Social Signal Score

57
5d
70
1 mentions
—
30d
50
3 mentions
—
60d
52
6 mentions
—
90d
54
9 mentions
—
news: 9

Analyst Ratings

6 analysts
Buyconsensus
Strong Buy 0Buy 4Hold 2Sell 0Strong Sell 0
Avg price target$6.67+613.4%
Low $4Median $7High $9
Current Consensus

Revenue

$5.66M+82.82%
$-2.07M$22.27M$46.61M$70.96M
Dec 2006Jun 2026

Analyst Estimates

FY2025
$-0.55
$-1.51–$-0.01
2 analysts
FY2026
$-0.05
$-0.15–$-0.00
1 analysts
FY2027
$-0.28
$-0.77–$-0.01
1 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Jonathan E. Dickinson
Sector
Healthcare
Industry
Biotechnology
Employees
163
Beta
0.88
Country
FR
Piotroski score
4 / 9 (Middling)
Altman Z-score
-22.70
www.innate-pharma.com